scintigraphy is an imaging modality that is used in the diagnostic evaluation of occult infections when other imaging modalities are either contraindicated or uninformative. Labeled leukocytes migrate to and accumulate at sites of inflammation, which are then visualized on nuclear imaging. 111 In-labeled WBC scans detect localized inflammation, but do not clearly distinguish between infectious and noninfectious inflammatory processes [1] . 111 In-labeled WBC scans have been used in the diagnostic evaluation of fever of unknown origin (FUO) [2] [3] [4] , prosthetic joint infections [3] , vascular graft infections [5] [6] [7] , and osteomyelitis [3, 8] .
Test performance characteristics are traditionally reported in terms of sensitivity, specificity, and overall diagnostic accuracy. Reported sensitivity of 111 In-labeled WBC scans for the diagnosis of infectious conditions ranged from 60% to 100% and specificity ranged from 69% to 92% in several series (Table 1) [2] [3] [4] [5] [7] [8] [9] . Furthermore, the sensitivity of 111 In-labeled WBC scans for detection of chronic infections is reported to be similar to that for detection of acute infections [10] . 111 In scans are often used as adjunctive tools in cases of diagnostic uncertainty. Providers look to the results of 111 In scans to inform clinical decision making. However, Wanahita et al postulated that, despite sensitivity and specificity >80%, 111 In-labeled WBC scans are not accurate enough to meaningfully impact clinical care in cases of difficult clinical decisions, such as whether or not to perform a revision arthroplasty on a suspected prosthetic joint infection [3] . This assertion warrants further evaluation. In the current era where increased emphasis is placed on decreasing waste and increasing value in clinical medicine, an assessment of the clinical utility of diagnostic tests must be considered.
The purpose of this investigation was to evaluate the historical use of 111 In-labeled WBC scans, and to assess the frequency with which 111 In-labeled WBC scans significantly impacted clinical care at our tertiary care center.
METHODS
All patients who underwent 111 In-labeled WBC scans at Duke University Hospital between January 1, 2005 and December 31, 2011 were identified via the Duke Enterprise Data Unified Content Explorer (DEDUCE), a tool utilized at our center to query multiple databases containing clinical data [11] . Patient demographic information, the clinical setting in which the scan was obtained (ie, outpatient vs inpatient), and the ordering provider and/or service were obtained utilizing this query tool. Two infectious disease physicians independently reviewed the electronic medical records of all patients who underwent 111
In-labeled WBC scans and obtained the following additional data elements: clinical indication for scan, scan result, diagnosis, and scan utility.
Clinical indications for scans were determined by review of provider documentation at the time the scan was ordered. Indications were categorized as one of the following: FUO, suspected osteomyelitis, suspected prosthetic device infection (eg, prosthetic joint, pacemaker), suspected vascular access infection (eg, dialysis graft), known other infection (eg, persistent staphylococcal bacteremia), or other.
Scan result was determined from the attending radiology report. The result was defined as positive if the radiology report described a focal, nonphysiologic change (generally a focal increase) in 111 In uptake that was subsequently found to be a site of infection. A scan result was defined as negative if the radiology report described no focal change in 111 In uptake, or if a focal change was found that did not correspond to the site of a subsequently confirmed infection. A scan result was defined as indeterminate if nonspecific changes in 111 In uptake were described, or if it was otherwise not possible to ascertain from the radiology report whether a focal increase in 111 In uptake was present, suggestive of infection. The final diagnosis was determined based on review of the comprehensive electronic medical record. Final diagnoses were categorized as infectious if the patient had clinical evidence of infection supported by appropriate microbiologic and pathologic data, noninfectious if an alternate diagnosis was made based on a combination of clinical, laboratory, and radiographic data (including, eg, follow-up with no evidence of emergent infection if antimicrobial therapy was not used), or indeterminate if a clear diagnosis was not evident after a review of all available medical records. Similar methodology using overall clinical assessment as the reference standard has been utilized previously in studies of the utility of 111 In-labeled WBC scans for diagnosis of infection [2] [3] [4] 12] . Each reviewer made an independent assessment of the clinical utility of the scan. Scans were categorized as clinically useful if they definitely or possibly contributed to subsequent clinical management decisions made about the patient. They were categorized as not clinically useful if they did not contribute to the clinical management of the patient. In some cases it was impossible to determine whether the scan was helpful in patient management, and these scans were categorized as having an unclear contribution to diagnosis or management. Examples of categories of clinical utility (with illustrative quotations from the medical record) follow:
• Positive scan, helpful: "Pushed surgery to remove graft in setting of persistent bacteremia."
• Positive scan, possibly helpful: "Patient with prior methicillin-sensitive Staphylococcus aureus endocarditis with scan that lit up in the brain; computed tomography and magnetic resonance imaging scans done around the same time showed enhancing lesions concerning for abscesses."
• Positive scan, not helpful: "Scan consistent with arteriovenous graft infection but surgery wouldn't remove, so prolonged antibiotics."
• Negative scan, helpful: "Disseminated Mycobacterium chelonae infection, no sign of graft infection."
• Negative scan, not helpful: "Negative scan but clinically thought to have infected graft which was removed and found to be infected."
When independent observers disagreed on the scan result or clinical utility of the scan, the case was discussed to arrive at a consensus decision; a final consensus was reached in all cases.
Descriptive statistics were used to describe and compare characteristics of patients whose scans were clinically useful vs those whose were not. Correlation of interrater observations was assessed using the κ statistic. Sensitivity and specificity of 111 Inlabeled WBC scans for diagnosis of infectious conditions were determined. Cases in which there were insufficient data to make a definitive diagnosis were excluded from the analysis of test sensitivity and specificity. Data analysis was performed using SAS version 9.3 (SAS Institute).
RESULTS
One hundred thirty-seven 111 In-labeled WBC scans were performed at our tertiary referral hospital during the 7-year study period. The number of scans that were performed each year decreased during the study period, from 26 scans in 2005 to 13 scans in 2011. Ninety-seven (71%) scans were performed on hospitalized patients, whereas the remaining scans were performed on outpatients. 111 In-labeled WBC scans were ordered by providers in a variety of specialties and subspecialties. Seventy-four (57%) scans were ordered by internal medicine specialists or subspecialists; 46 (36%) scans were ordered by general surgeons or surgical subspecialists, including 27 (21%) scans ordered by orthopedic surgeons; and 9 scans were ordered by miscellaneous other specialists (Table 2) . ). Ultimately, a definitive diagnosis of infection was made in 85 (62%) cases and a definitive diagnosis of a noninfectious condition was made in 32 (23%) cases. There were insufficient data to make a definitive diagnosis in 20 (15%) cases. Detailed description of scan indications, results, and final diagnoses is included in Table 3 .
The overall sensitivity of WBC scans for diagnosing any infection was 0.43; the specificity for infection was 0.90. In addition, we also assessed the sensitivity and specificity for the 3 most common scan indications (Table 4) . Overall, in our population the positive predictive value of a positive 111 In-labeled WBC scan for infection was 0.92, whereas the negative predictive value of 111 In-labeled WBC scans for infection was 0.37. Interestingly, the independent reviewers disagreed regarding the scan result ( positive vs negative) in 13 cases. These disagreements all related to ambiguity in the radiology reports, and were resolved after reevaluation using strict interpretations of the predefined study criteria. After initial, independent review, observers agreed on the clinical utility (helpful or not helpful) in 97 (70%) cases (κ = 0.45). The 2 observers discussed each case in which individual observations regarding clinical utility In-labeled WBC scan results impacted clinical care less than half of the time at our center. We believe that our findings are meaningful and must be considered by clinicians in the process of diagnostic decision making.
Our approach to this evaluation is unique, as we focused primarily on the clinical utility rather than traditional measures of diagnostic accuracy. We assert that diagnostic tests provide benefit (both to clinicians and consumers of medical care) when the results meaningfully impact subsequent clinical care. In this way, both positive and negative tests can be highly beneficial. Others have reported clinical utility of nuclear imaging tests as the proportion of tests that led to a final diagnosis. Thus, In-labeled WBC scans differed depending on the clinical indication for the scan. Scans were more helpful in the management of suspected vascular access infections and osteomyelitis than FUO. This is not unexpected, given the heterogeneity of diseases encompassed by the syndrome of FUO and the known difficulty in diagnosing the etiology of FUO even in the modern era of improved cross-sectional imaging [15] . Positive scans were more likely to be helpful than negative scans. The sensitivity of 111 In-labeled WBC scans for the diagnosis of infectious conditions was <50%, which is lower than values reported by others [2, 3, 7, 8, 10] . Therefore, the decreased utility among negative scans at our center may reflect an appropriate perception by prescribing physicians of the uncertainty of negative test results. Clear written and spoken communication between prescribing physicians and consultants is essential to medical practice. This is exemplified by our findings. Independent reviewers initially disagreed regarding the scan result in approximately 10% of cases. The disagreement was felt to relate to ambiguous wording of radiology reports. As noted above, 111 In-labeled WBC scans are performed infrequently at our hospital. Inexperience by providers and interpreting radiologists may have contributed to uncertainty that led to difficulty in conveying or interpreting results. Furthermore, poor interrater agreement has been previously reported for leukocyte scintigraphy. In one study, only 65% of radiologists provided the same interpretation (high, intermediate, or low probability of infection), and an interpretation of "intermediate probability" was given nearly 20% of the time [16] . Clinical utility of any test will be influenced by the consistency and clarity with which findings are reported. A standardized way of reporting scan results (as opposed to freetext reporting) may be one way to improve the clinical utility of complex tests such as 111
In-labeled WBC scans; such standardized reporting using checklists has been advocated for other radiographic studies [17] . While 111
In-labeled WBC scintigraphy was the most common method of nuclear imaging utilized for the detection of infection at our institution during the time of the study, other radiopharmaceuticals can be used for this purpose. Gallium 67 ( 67 Ga) citrate accumulates in body sites due to increased vascular permeability; therefore, one advantage of gallium scans is that no ex vivo cell labeling is required. However, in practice, the utility of gallium scans is limited by their lack of specificity and requirement for waiting periods up to 72 hours between injection and imaging [1, 18] . 111 In oxine and Technetium 99m ( 99m Tc)-hexamethylpropyleneamine oxime (HMPAO)
are the most common agents used to label WBCs [19] . The 2 labeling techniques have some important differences. 111 Inlabeling is recommended over 99m Tc for imaging the urinary tract and gallbladder, because excretion of 99m Tc occurs via these routes [18] [19] [20] . 111 In labeling is preferred for indications Tc labeling may play a specific role in evaluation of inflammatory bowel disease or acute soft tissue infections [19, 20] . Other radiopharmaceuticals, including cytokines and antimicrobials, have been proposed but are not available for clinical use in the United States at this time [18] . Unfortunately, no one modality performs superiorly for all clinical scenarios, and, thus, understanding the strengths and weaknesses of each can help providers pursue the test most likely to provide the greatest value.
Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET), which is primarily used for localization of malignancy, has also demonstrated utility for the detection of infection or inflammation [18, 21] . In one retrospective study, FDG-PET imaging was abnormal in 15 of 35 (43%) patients with FUO, and led to the diagnosis of the etiology in 13 (37%) patients. In the same study, FDG-PET was abnormal in 38 of 55 (69%) cases of suspected localized infection or inflammation and contributed to the eventual diagnosis in 36 (65%) cases [13] . The authors reported high sensitivity (93%, 100%) and specificity (90%, 89%) of FDG-PET for the diagnosis of FUO and localized infection, respectively [13] . Pill In-labeled WBC together had a sensitivity and specificity of 50% and 95%, respectively. Similarly, Seshadri et al prospectively compared FDG-PET to 111 In-labeled WBC scintigraphy for the evaluation of FUO [23] . The sensitivity of FDG-PET for determining the etiology of FUO was 86% whereas the sensitivity of 111 In-labeled WBC scintigraphy was only 20% [23] . Thus, FDG-PET imaging has demonstrated greater sensitivity than 111
In-labeled WBC scintigraphy in small, prospective comparisons. At this time, high cost and lack of reimbursement by insurance companies for noncancer indications hinder FDG-PET's more widespread use. However, FDG-PET may eventually supplant other modalities of nuclear imaging for the diagnosis of suspected infection.
We acknowledge several limitations to the current study. First, the study was performed at a single tertiary medical center in which the utilization of 111 In-labeled WBC scans was relatively infrequent. Our results may not be generalizable to other settings, especially those in which nuclear imaging studies are performed commonly or are incorporated into established diagnostic algorithms. Second, assessing the clinical utility as we have done is inherently subjective. Despite using standardized, a priori definitions of clinical utility, independent reviewers initially disagreed in a minority of cases. Furthermore, determination of utility was made by retrospective review, requiring reviewers to extrapolate cause-effect relationships from the electronic medical record. If clinicians had been interviewed in real time to assess the role of the scans in decision making, the perceived utility of the scans would possibly have been higher. However, prospective interviews may have introduced bias by impacting scan prescribing practices or subsequent patient care decisions.
In the current era of increasing emphasis on cost-conscious and accountable care, appropriate utilization of expensive and logistically challenging tests is vital. 111 In-labeled WBC scans are clinically useful in a minority of cases. Targeting ordering of these scans for conditions in which they are most likely to impact clinical care, including vascular graft infections and osteomyelitis, would optimize resource utilization.
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